Neuromyelitis optica spectrum disorder
Drug research and approvals for neuromyelitis optica spectrum disorder: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 47 studies of neuromyelitis optica spectrum disorder are recruiting on ClinicalTrials.gov, Health Canada has authorized 11 drug trials for it since 2013, and FDA has 4 approved and 4 open orphan designations naming it.
- Recruiting worldwide: 47
- Trials authorized in Canada: 11
- FDA orphan approvals: 4
- EU medicines: 0
Recruiting Now
Newest start dates first, of 47 recruiting on ClinicalTrials.gov ↗- Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During…NCT05909761 · Not reported · Amgen · starts Jan 15, 2027
- Safety and Efficacy Study of Sivelestat in Neuromyelitis Optica Spectrum DisorderNCT07738952 · Phase 1 / Phase 2 · Kyushu University · starts Oct 1, 2026
- Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSDNCT07010302 · Phase 4 · Massachusetts General Hospital · starts Sep 1, 2026
- A Multicenter Prospective Real-World Effectiveness and Safety of Satralizumab in the Early Treatment of Attacks in NMOSDNCT07762872 · Not reported · Junwei Hao, MD · starts Jul 20, 2026
- Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With…NCT07557420 · Phase 3 · Alexion Pharmaceuticals, Inc. · starts Jul 20, 2026
- A Study to Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, and Pharmacodynamics of Satralizumab in Pediatric…NCT05199688 · Phase 3 · Hoffmann-La Roche · starts May 6, 2026
- Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory…NCT07526493 · Phase 1 · Tongji Hospital · starts Apr 1, 2026
- Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World StudyNCT07410039 · Phase 4 · Chinese PLA General Hospital · starts Feb 1, 2026
- Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum DisorderNCT07420296 · Phase 3 · Tianjin Medical University General Hospital · starts Jan 1, 2026
- Efficacy and Safety of Transcranial Temporal Interference Stimulation (tTIS) for Neuropathic Pain in Neuromyelitis…NCT07377305 · Not applicable · Tang-Du Hospital · starts Dec 8, 2025
Trials Authorized in Canada
The 10 newest of 11; search them all in Canada trials| Dec 7, 2022 | A phase I, multicenter, open-label, uncontrolled study to evaluate pharmacokinetics, pharmacodynamics, safety, and tolerability of satralizumab in adult…ENSPRYNG | Roche | Closed |
| May 16, 2022 | A phase 2/3, open-label, historical-controlled, single-arm, multicenter smdy to evaluate the efficacy, pharmacokinetics, pharmacodynamics, and safety of…ALXN1210 | AstraZeneca Pharmaceuticals LP | Ongoing |
| May 9, 2022 | An open-label multicenter study to evaluate the pharmacokinetics, pharmacodynamics, and safety of inebilizumab in pediatric subjects with neuromyelitis optica…INEBILIZUMAB (VIB0551) | Amgen | Pending |
| Nov 5, 2021 | Sakurabonsai: clinical, imaging and biomarker open-label study in neuromyelitis optica spectrum disorder (nmosd) with satralizumab as an interventionSATRALIZUMAB (RO5333787) (SA237) | Roche | Ongoing |
| Nov 3, 2020 | A multicenter, single arm, open-label study to evaluate the long-term safety and efficacy of satralizumab in patients with neuromyelitis optica spectrum…ENSPRYNG | Roche | Ongoing |
| Nov 13, 2019 | A phase 2/3 open-label, single-arm trial to evaluate the safety and activity of eculizumab in pediatric patients with relapsing neuromyelitis optica spectrum…SOLIRIS | AstraZeneca Pharmaceuticals LP | Ongoing |
| Oct 29, 2019 | A phase 3, external placebo-controlled, open-label, multicenter study to evaluate the efficacy and safety of ravulizumab in adult patients with neuromyelitis…ALXN1210 | AstraZeneca Pharmaceuticals LP | Ongoing |
| Apr 11, 2014 | A multicenter, randomized, double-blind, placebo-controlled phase 3 study to evaluate the efficacy and safety, of sa237 as monotherapy in patients with…SA237 | Roche | Ongoing |
| Mar 20, 2014 | A double-masked, placebo-controlled study with open label period to evaluate the efficacy and safety of medi-551 in adult subjects with neuromyelitis optica…MEDI-551 | MEDIMMUNE LLC | Closed |
| Jun 27, 2013 | A phase III, open-label, extension trial of ecu-nmo-301 to evaluate the safety and efficacy of eculizumab in patients with relapsing neuromyelitis (nmo)SOLIRIS | AstraZeneca Pharmaceuticals LP | Pending |
FDA Orphan Designations
Approved first, then open designations, newest first| Mar 22, 2024 | Ultomiristreatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody positive | Alexion Pharmaceuticals, Inc. | Approved |
| Aug 14, 2020 | Enspryngtreatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive | Genentech, Inc. | Approved |
| Jun 11, 2020 | UpliznaUplizna is indicated for for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4… | Horizon Therapeutics Ireland DAC | Approved |
| Jun 27, 2019 | SolirisSoliris is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4)… | Alexion Pharmaceuticals, Inc. | Approved |
| Feb 2, 2026 | rituximabtreatment of neuromyelitis optica spectrum disorder | ODDIFACT SAS | Designated |
| Apr 24, 2023 | EdralbrutinibTreatment of neuromyelitis optica spectrum disorder | eVenus Pharmaceutical Lab Inc. | Designated |
| Aug 25, 2016 | ublituximabTreatment of neuromyelitis optica and neuromyelitis optica spectrum disorder | TG Therapeutics, Inc. | Designated |
| Mar 19, 2015 | cladribineTreatment of neuromyelitis optica and neuromyelitis optica spectrum disorder | Chord Therapeutics S.a.r.l. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA